HRD + BRCA wild-type

In the BRCA+ high-risk population, olaparib monotherapy (median PFS 41.2 months) and olaparib plus bevacizumab (median PFS 42.5 months) demonstrated the greatest PFS benefit, marginally outperforming niraparib (median PFS 31.2 months). RMST analysis also indicated an advantage of 8.5 months for the combination, though this did not reach statistical significance. PARPi treatment benefit in ovarian cancer is meaningfully influenced by genetic profile and relapse risk, supporting biomarker-driven treatment selection in clinical practice.

The HRd rate in this Taiwanese cohort aligns with existing literature. PARPi significantly improved survival in HRd patients, but adverse events necessitate careful hematological monitoring for treatment sustainability.

These findings highlight that EDA-FN is an excellent target for HGSOC, while CEA could serve as a potential target for MOC. Clinical investigations are warranted to evaluate innovative treatments in ovarian cancer targeting these antigens.

P=N/A, N=400, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

Conclusion These results demonstrate an association between T-cell exhaustion and HRD. T-cell exhaustion is an independent predictor of disease outcome in HGSOC.

Sponsored by Takeda

The analysis included 50 OC MDT members. Respondents were mainly based in England (84%; 42/50). Most HCPs (68%; 19/28) used the DESKTOP-III criteria to identify candidates for secondary cytoreduction, with up to 30% of patients considered as eligible in 85% (23/27) of centres.

Platinum-sensitive patients typically received PARPi maintenance therapy, irrespective of HRD status. Most HCPs used DESKTOP-III criteria to determine secondary debulking candidates at first relapse.

P=N/A, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P=N/A, N=400, Not yet recruiting, AstraZeneca

On the other hand , subgroup analyses of Paola 1 indicated a greater benefit for the combination of olaparib and bevacizumab in patients at lower risk of recurrence, i.e., patients without residual disease after primary debulking surgery. Several ongoing trials (e.g., NIRVANA-1, AGO-OVAR 28/ENGOT-ov57) are currently evaluating the contribution of adding bevacizumab to PARPi and will provide further evidence on this subject. Moreover, the magnitude of benefit from the combination could also depend on the location and type of HR gene mutations, and additional research is warranted to deepen our knowledge of the predictive role of the exact “causes” behind HR deficiency.

A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.